TABLE 2.
Treatment proposed to be evaluated by the included records (n = 157)
| Treatments | n | % |
|---|---|---|
| Unclear | 19 | 11.9 |
| Traditional Chinese medicine | 19 | 11.9 |
| Chloroquine and/or hydroxychloroquine | 12 | 7.5 |
| Traditional Chinese and Western medicine | 6 | 3.8 |
| Lianhua Qingwen capsules | 5 | 3.1 |
| Blood components | 5 | 3.1 |
| Acupuncture | 4 | 2.5 |
| Corticosteroids | 4 | 2.5 |
| Different types of treatment | 4 | 2.5 |
| Favipiravir | 3 | 1.9 |
| Lopinavir/ritonavir | 3 | 1.9 |
| Pharmacological treatment | 3 | 1.9 |
| Physiotherapy techniques | 2 | 1.3 |
| Angiotensin‐converting enzyme inhibitors and angiotensin II receptor blockers | 2 | 1.3 |
| Atazanavir | 2 | 1.3 |
| Chloroquine plus azithromycin | 2 | 1.3 |
| Extra corporeal membrane oxygenation | 2 | 1.3 |
| External treatment of traditional Chinese medicine | 2 | 1.3 |
| Immunosuppressive drugs | 2 | 1.3 |
| Interferon | 2 | 1.3 |
| Jinhua Qinggan granule | 2 | 1.3 |
| Noninvasive ventilation | 2 | 1.3 |
| Qing Fei Bai Du decoction | 2 | 1.3 |
| Remdesivir | 2 | 1.3 |
| Ribavirin | 2 | 1.3 |
| Chinese Herbal medicine | 2 | 1.3 |
| Traditional medicine as adjunctive therapy | 2 | 1.3 |
| Xuebijing injection | 2 | 1.3 |
| Favipiravir and remdesivir | 1 | 0.6 |
| Interleukin 1 inhibitor agents (specifically Anakinra) VS anti‐IL6 monoclonal antibodies (tocilizumab, sarilumab, siltuximab) | 1 | 0.6 |
| Traditional Chinese medicine injections | 1 | 0.6 |
| Volume‐controlled ventilation | 1 | 0.6 |
| Adjuvant pharmacologic therapy, standard care, definitive pharmacologic therapy, combined definitive pharmacologic | 1 | 0.6 |
| Advanced respiratory support; basic respiratory support | 1 | 0.6 |
| All suggested pharmacological therapies | 1 | 0.6 |
| Arbidol | 1 | 0.6 |
| Antiparasitic drugs | 1 | 0.6 |
| Antiviral drugs | 1 | 0.6 |
| Bacillus Calmette–Guérin vaccine (BCG) vaccination | 1 | 0.6 |
| Chinese exercise | 1 | 0.6 |
| Combination of traditional Chinese and Western medicine | 1 | 0.6 |
| Convalescent plasma transfusion vs standard care | 1 | 0.6 |
| Convalescent plasma or hyperimmune immunoglobulin | 1 | 0.6 |
| Enoxaparin or fondaparinux | 1 | 0.6 |
| Favipiravir, remdesivir, galidesivir, ivermectin, oseltamivir, ganciclovir, lopinavir/ ritonavir, darunavir, chloroquine, hydroxychloroquine, arbidol, azithromycin, amoxicillin, moxifloxacin, ceftriaxone, antifungals, androgen receptor blockers, tea, and traditional Chinese medicine | 1 | 0.6 |
| Hydroxychloroquine vs azithromycin | 1 | 0.6 |
| Hydroxychloroquine vs standard treatment | 1 | 0.6 |
| Interferons alone or in combination with other drugs | 1 | 0.6 |
| Lopinavir combined with ritonavir | 1 | 0.6 |
| Integrative traditional Chinese and Western medicine | 1 | 0.6 |
| Interferon, lopinavir, ritonavir, ribavirin, remdesivir | 1 | 0.6 |
| Rheumatic disease therapy | 1 | 0.6 |
| Monoclonal antibodies | 1 | 0.6 |
| Macrolides | 1 | 0.6 |
| Mesenchymal stem cell‐based therapy | 1 | 0.6 |
| Vitamin C | 1 | 0.6 |
| Tocilizumab alone, tocilizumab combination therapy with antivirals and/or other drugs | 1 | 0.6 |
| Siddha medicine | 1 | 0.6 |
| Pharmacological interventions, fluid therapy, invasive or noninvasive ventilation, or similar interventions | 1 | 0.6 |
| Qingfei Paidu decoction | 1 | 0.6 |
| Traditional Chinese exercise | 1 | 0.6 |
| Moxibustion | 1 | 0.6 |
| Tai Chi | 1 | 0.6 |
| Traditional Chinese medicine nonpharmacological interventions | 1 | 0.6 |
| Pharmacologic and nonpharmacologic | 1 | 0.6 |
| Massage therapy | 1 | 0.6 |
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.